Cart
sales@molnova.com
LY2835219 mesylate
CAS No. 1231930-82-7
LY2835219 mesylate ( Abemaciclib )
Catalog No. M10916 CAS No. 1231930-82-7
LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 27 | In Stock |
|
| 5MG | 45 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 77 | In Stock |
|
| 50MG | 88 | In Stock |
|
| 100MG | 113 | In Stock |
|
| 200MG | 141 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY2835219 mesylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
-
DescriptionLY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
-
SynonymsAbemaciclib
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK4; CDK6
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1231930-82-7
-
Formula Weight602.70
-
Molecular FormulaC27H32F2N8·CH4O3S
-
Purity>98%(HPLC)
-
SolubilityEthanol: 24 mg/mL (39.82 mM); Water: 100 mg/mL (165.92 mM); DMSO: 83 mg/mL (137.71 mM)
-
SMILESCS(O)(=O)=O.CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(=N3)C3=CC4=C(N=C(C)N4C(C)C)C(F)=C3)C=C2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sanchez-Martinez et al. Mol Y Ther, 2011,10(11 Suppl), Abstract nr B234.
molnova catalog
related products
-
NSC 625987
NSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E).
-
HQ461
HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.
-
Dinaciclib
A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
